Tandem t:slim Mobile App Now Available in Canada

Key Terms

bolus medical

A bolus is a single, concentrated dose of a drug or fluid given all at once rather than slowly over time, like taking a quick gulp instead of sipping. Investors should care because a bolus can change how fast a medicine works, its side effect risks, and how regulators view dosing safety; those factors can materially affect clinical trial outcomes, approval chances and commercial prospects.

basal medical

Basal describes a basic, underlying or resting level of something, often used in medicine to mean the background rate or baseline measurement (for example, basal insulin release or basal metabolic rate). For investors, knowing a basal value matters because it sets the reference point used to judge whether a drug, treatment or metric produces a meaningful change—like comparing a resting heart rate to one measured after exercise to see if an intervention truly moves the needle.

cloud-based technical

Software, data or services that run on remote computers accessed over the internet instead of on a user’s own device; think of renting storage, apps and computing power in someone else’s warehouse rather than buying and maintaining the gear yourself. Investors care because cloud-based models can lower a company’s upfront costs, speed product updates, scale quickly with demand and create recurring revenue, all of which affect cash flow, growth prospects and valuation.

insulin pump medical

A small wearable medical device that delivers measured doses of insulin automatically or on demand to help people with diabetes regulate their blood sugar, often replacing multiple daily injections. Investors care because these devices combine hardware, software and supplies to create recurring revenue, are subject to regulatory approval and reimbursement decisions, and can change competitive dynamics in a large, growing healthcare market much like a smartphone platform reshapes accessory sales.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM) a leading insulin delivery and diabetes technology company, today announced availability of the Tandem t:slim mobile application for Android and iOS users in Canada. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.¹

“With this release, we are furthering our commitment to expand our innovative, integrated solutions to customers worldwide,” said John Sheridan, president and chief executive officer. “We are thrilled to be able to bring the benefits of the Tandem t:slim mobile app to our customers in Canada for both iOS and Android devices.”

The Tandem t:slim mobile app is a secure, user-friendly mobile application that, when paired with a t:slim X2 insulin pump, displays the user’s pump information on their personal smartphone. In addition to the ability to deliver and cancel a bolus, the mobile app displays the last 24 hours of glucose trends, pump status changes, and insulin therapy data, including basal and bolus deliveries and suspensions of insulin delivery. The app also displays pump alerts and alarms, and it securely uploads data into the cloud-based Tandem Source platform wirelessly. Importantly, the t:slim X2 insulin pump functions independently from the Tandem t:slim mobile app, therefore a user always retains the freedom to view pump therapy data, program requests and cancel or stop bolus insulin requests from their pump.

The Tandem t:slim mobile app is available for download in the Apple App Store and Google Play now. Eligible customers will receive an email with instructions on how to download and use the app. Users must be on t:slim X2 insulin pump version 7.8.1 or above to pair their pump with a compatible smartphone and begin using the mobile app.

1

The information on the Tandem t:slim mobile app display may not be identical to the current status of the user’s pump. Wireless uploads from the Tandem t:slim mobile app to the cloud-based Tandem Source platform require a compatible phone and an internet or wireless data connection. Uploads to the Tandem Source platform do not take place in real time and should not be relied upon by healthcare providers or caregivers for remote patient monitoring. Standard carrier data rates may apply.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

Follow @TandemDiabetesCare on TikTok and @TandemDiabetes on Facebook, Instagram, LinkedIn, and X.

Forward-looking Statements

This press release contains both U.S. “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and Canadian "forward-looking information" within the meaning of applicable Canadian securities laws, collectively “forward-looking statements”. These forward-looking statements relate to, among other things, our continued ability to provide and expand availability of the Tandem t:slim mobile app on one or both the Apple and Google Play app stores. These and other risks are identified and described in greater detail under the “Risk Factors” heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.

Important Safety Information

This product may not be right for you. Always read the label and follow the directions for use. The t:slim X2 insulin pump is indicated for the treatment of diabetes mellitus in individuals 6 years of age and greater.

The Tandem t:slim mobile app is an accessory intended for use as a connected software device that is able to reliably and securely communicate with compatible insulin pumps, including receiving and displaying pump information and sending insulin delivery commands to a user's connected and compatible t:slim X2 insulin pump.

The Tandem Source platform is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.

© 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. App Store is a registered trademark of Apple Inc. Google Play is a trademark of Google LLC. All other third-party marks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251218516273/en/

Media Contact:

858-366-6900

media@tandemdiabetes.com

Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.